Alnylam Pharmaceuticals up over 12%, on Pace for Largest Percent Increase Since July 2025

Dow Jones
Jul 09

Alnylam Pharmaceuticals, Inc $(ALNY)$ is currently at $362.53, up $39.03 or 12.06%

 

--Would be highest close since Jan. 22, 2026, when it closed at $370.00

--On pace for largest percent increase since July 31, 2025, when it rose 15.43%

--Currently up eight consecutive days; up 24.42% over this period

--Longest winning streak since Oct. 20, 2025, when it rose for eight straight trading days

--Best eight day stretch since the eight days ending Aug. 11, 2025, when it rose 28.02%

--Up 20.43% month-to-date

--Down 8.83% year-to-date

--Down 26.2% from its all-time closing high of $491.22 on Oct. 20, 2025

--Up 12.36% from 52 weeks ago (July 10, 2025), when it closed at $322.64

--Down 26.2% from its 52-week closing high of $491.22 on Oct. 20, 2025

--Up 30.36% from its 52-week closing low of $278.09 on June 18, 2026

--Traded as high as $380.00; highest intraday level since Jan. 9, 2026, when it hit $409.58

--Up 17.47% at today's intraday high; largest intraday percent increase since July 31, 2025, when it rose as much as 18.43%

--Second best performer in the Nasdaq 100 today

 

All data as of 10:06:42 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

July 09, 2026 10:08 ET (14:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10